Figure 2.
Impact of dosing and frequency adjustment (on-treatment population). For W24 and W48, absolute (SE) LDL-C values for the alirocumab groups are presented on the graph.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.